Trinity Biotech (TRIB) Accounts Payables (2009 - 2025)

Trinity Biotech (TRIB) has reported Accounts Payables for 17 consecutive years, with $29.7 million the latest figure, recorded in Q4 2025.

• Quarterly Accounts Payables rose 10.91% year-over-year to $29.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $29.7 million (up 10.91% YoY) and the FY2025 annual result came in at $29.7 million, up 10.91% from the prior year.
• Accounts Payables climbed to $29.7 million in Q4 2025 per TRIB's latest filing, from $26.5 million in the prior quarter.
• Over the last five years, Accounts Payables for TRIB reached as high as $30.9 million in Q1 2021 and fell as low as $12.2 million in Q3 2023.
• A 5-year average of $19.3 million and a median of $17.0 million in 2021 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2022 — Accounts Payables tumbled 49.36% — and 2024, when it jumped 109.2%.
• Year by year, Accounts Payables stood at $15.1 million in 2021, then climbed by 1.64% to $15.4 million in 2022, then slipped by 16.73% to $12.8 million in 2023, then soared by 109.2% to $26.8 million in 2024, then climbed by 10.91% to $29.7 million in 2025.
• According to Business Quant data, Accounts Payables over the past three periods registered $29.7 million, $26.5 million, and $26.8 million for Q4 2025, Q2 2025, and Q4 2024 respectively.